A Contrarian Bet Emerges for Ocugen Shares

Ocugen US67577C1053

Friday’s trading activity for Ocugen presented a market conundrum. While the share price itself declined, a surge in bullish options trading painted a starkly different picture, suggesting some investors are positioning for a potential reversal.

Adding a layer of institutional intrigue, Vanguard Group recently increased its stake in the biopharmaceutical company. The asset manager added approximately 451,000 shares, bringing its total holdings to about 15.2 million. This vote of confidence from a major investor stands in contrast to the firm’s recent financial performance. For the third quarter, Ocugen reported a per-share loss of $0.07, which fell short of the $0.06 loss anticipated by analysts.

Explosive Options Activity Defies Stock Price Movement